|Nausea||107 (50)||11 (5)|
|Diarrhea||91 (43)||17 (8)|
|Vomiting||73 (34)||4 (2)|
|Metabolism and nutrition disorders|
|Decreased appetite||73 (34)||9 (4)|
|Tumor lysis syndrome (TLS)b||13 (6)||12 (6)|
|Blood and lymphatic system disorders|
|Differentiation syndromec||29 (14)||15 (7)|
|Noninfectious leukocytosis||26 (12)||12 (6)|
|Nervous system disorders|
|Dysgeusia||25 (12)||0 (0)|
aGastrointestinal disorders observed with IDHIFA® treatment can be associated with other commonly reported events, such as abdominal pain and weight decrease.
bTLS observed with IDHIFA® treatment can be associated with commonly reported uric acid increase.
cDifferentiation syndrome can be associated with other commonly reported events such as respiratory failure, dyspnea, hypoxia, pyrexia, peripheral edema, rash, or renal insufficiency.
|Parametera||All grades (%)||≥Grade 3 (%)|
|Total bilirubin increased||81||15|
aIncludes abnormalities occurring up to 28 days after last IDHIFA® dose, if new or worsened by at least 1 grade from baseline, or if baseline was unknown. The denominator varies based on data collected for each parameter (N=213, except phosphorus [N=209]).
The median duration of exposure to IDHIFA® was 4.3 months (range, 0.3 to 23.6).
IDHIFA® demonstrated 30-day and 60-day mortality rates of 4.2% (9/214) and 11.7% (25/214), respectively.
Other clinically significant ARs occurring in ≤10% of patients included Respiratory, Thoracic, and Mediastinal Disorders (pulmonary edema, acute respiratory distress syndrome).
43% of patients experienced an AR leading to a dose interruption
5% of patients had a dose reduction due to an AR
17% of patients permanently discontinued therapy due to an AR
Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells. It may be life-threatening or fatal if not treated.
Symptoms observed in patients treated with IDHIFA®
While there is no diagnostic test for differentiation syndrome, symptoms in patients treated with IDHIFA® included:
Differentiation syndrome has been observed with and without concomitant hyperleukocytosis in as early as 1 day and up to 5 months after IDHIFA® initiation
Explore important topics in managing patients who have R/R AML with an IDH2 mutation receiving IDHIFA®, including diagnosing and treating differentiation syndrome and other adverse events.
Based on animal embryo-fetal toxicity studies, IDHIFA® can cause embryo-fetal harm when administered to a pregnant woman.
IDHIFA® may interfere with bilirubin metabolism through inhibition of UGT1A1.
12% of patients experienced leukocytosis
Tumor lysis syndrome
6% of patients experienced TLS
Patients must meet the following criteria to enroll:
Additional Terms and Conditions of the Celgene Commercial Co-pay Programs
© 2017 Celgene Corporation 06/17 US-CELG170216